H2N2V1, Ncbi, Merge, bibRecord, 000228

Increased Survival after Gemfibrozil Treatment of Severe Mouse Influenza▿

Identifieur interne : 000228 ( Ncbi/Merge ); précédent : 000227; suivant : 000229

Increased Survival after Gemfibrozil Treatment of Severe Mouse Influenza▿

Auteurs : Alison Budd ; Lisa Alleva ; Mohammed Alsharifi ; Aulikki Koskinen ; Victoria Smythe ; Arno Müllbacher ; Jeff Wood ; Ian Clark

Source :

Antimicrobial Agents and Chemotherapy [ 0066-4804 ] ; 2007.

RBID : PMC:1932503

Descripteurs français

KwdFr :
- Animaux, Anti-inflammatoires (administration et posologie), Anti-inflammatoires (usage thérapeutique), Gemfibrozil (administration et posologie), Gemfibrozil (usage thérapeutique), Hypolipémiants (administration et posologie), Hypolipémiants (usage thérapeutique), Infections à Orthomyxoviridae (immunologie), Infections à Orthomyxoviridae (mortalité), Infections à Orthomyxoviridae (traitement médicamenteux), Infections à Orthomyxoviridae (virologie), Inflammation (mortalité), Inflammation (traitement médicamenteux), Inflammation (virologie), Résultat thérapeutique, Souris, Souris de lignée BALB C, Sous-type H2N2 du virus de la grippe A (), Sous-type H2N2 du virus de la grippe A (pathogénicité).
MESH :
- administration et posologie : Anti-inflammatoires, Gemfibrozil, Hypolipémiants.
- immunologie : Infections à Orthomyxoviridae.
- mortalité : Infections à Orthomyxoviridae, Inflammation.
- pathogénicité : Sous-type H2N2 du virus de la grippe A.
- traitement médicamenteux : Infections à Orthomyxoviridae, Inflammation.
- usage thérapeutique : Anti-inflammatoires, Gemfibrozil, Hypolipémiants.
- virologie : Infections à Orthomyxoviridae, Inflammation.
- Animaux, Résultat thérapeutique, Souris, Souris de lignée BALB C, Sous-type H2N2 du virus de la grippe A.

English descriptors

KwdEn :
- Animals, Anti-Inflammatory Agents (administration & dosage), Anti-Inflammatory Agents (therapeutic use), Gemfibrozil (administration & dosage), Gemfibrozil (therapeutic use), Hypolipidemic Agents (administration & dosage), Hypolipidemic Agents (therapeutic use), Inflammation (drug therapy), Inflammation (mortality), Inflammation (virology), Influenza A Virus, H2N2 Subtype (drug effects), Influenza A Virus, H2N2 Subtype (pathogenicity), Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections (drug therapy), Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (mortality), Orthomyxoviridae Infections (virology), Treatment Outcome.
MESH :
- chemical , administration & dosage : Anti-Inflammatory Agents, Gemfibrozil, Hypolipidemic Agents.
- chemical , therapeutic use : Anti-Inflammatory Agents, Gemfibrozil, Hypolipidemic Agents.
- drug effects : Influenza A Virus, H2N2 Subtype.
- drug therapy : Inflammation, Orthomyxoviridae Infections.
- immunology : Orthomyxoviridae Infections.
- mortality : Inflammation, Orthomyxoviridae Infections.
- pathogenicity : Influenza A Virus, H2N2 Subtype.
- virology : Inflammation, Orthomyxoviridae Infections.
- Animals, Mice, Mice, Inbred BALB C, Treatment Outcome.

Abstract

Gemfibrozil, an agent that inhibits production of proinflammatory cytokines in addition to its clinically useful lipid-lowering activity, increased survival in BALB/c mice that were already ill from infection by influenza virus A/Japan/305/57 (H2N2). Gemfibrozil was administered intraperitoneally once daily from days 4 to 10 after intranasal exposure to the virus. Survival increased from 26% in vehicle-treated mice (n = 50) to 52% in mice given gemfibrozil at 60 mg/kg/day (n = 46) (P = 0.0026). If this principle translates to patients, a drug already approved for human use, albeit by a different route for another purpose, might be adapted relatively fast for use against influenza, conceivably including human infection with a derivative of the avian H5N1 strain.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1932503

DOI: 10.1128/AAC.00219-07
PubMed: 17562808
PubMed Central: 1932503

Links toward previous steps (curation, corpus...)

to stream Pmc, to step Corpus: 000263
to stream Pmc, to step Curation: 000263
to stream Pmc, to step Checkpoint: 000B61
to stream PubMed, to step Corpus: 000281
to stream PubMed, to step Curation: 000281
to stream PubMed, to step Checkpoint: 000258

Links to Exploration step

PMC:1932503

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Increased Survival after Gemfibrozil Treatment of Severe Mouse Influenza<xref ref-type="fn" rid="fn2">▿</xref>
 </title>
<author><name sortKey="Budd, Alison" sort="Budd, Alison" uniqKey="Budd A" first="Alison" last="Budd">Alison Budd</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Alleva, Lisa" sort="Alleva, Lisa" uniqKey="Alleva L" first="Lisa" last="Alleva">Lisa Alleva</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Alsharifi, Mohammed" sort="Alsharifi, Mohammed" uniqKey="Alsharifi M" first="Mohammed" last="Alsharifi">Mohammed Alsharifi</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Koskinen, Aulikki" sort="Koskinen, Aulikki" uniqKey="Koskinen A" first="Aulikki" last="Koskinen">Aulikki Koskinen</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Smythe, Victoria" sort="Smythe, Victoria" uniqKey="Smythe V" first="Victoria" last="Smythe">Victoria Smythe</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mullbacher, Arno" sort="Mullbacher, Arno" uniqKey="Mullbacher A" first="Arno" last="Müllbacher">Arno Müllbacher</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wood, Jeff" sort="Wood, Jeff" uniqKey="Wood J" first="Jeff" last="Wood">Jeff Wood</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Clark, Ian" sort="Clark, Ian" uniqKey="Clark I" first="Ian" last="Clark">Ian Clark</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">17562808</idno>
<idno type="pmc">1932503</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1932503</idno>
<idno type="RBID">PMC:1932503</idno>
<idno type="doi">10.1128/AAC.00219-07</idno>
<date when="2007">2007</date>
<idno type="wicri:Area/Pmc/Corpus">000263</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000263</idno>
<idno type="wicri:Area/Pmc/Curation">000263</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000263</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000B61</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000B61</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17562808</idno>
<idno type="wicri:Area/PubMed/Corpus">000281</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000281</idno>
<idno type="wicri:Area/PubMed/Curation">000281</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000281</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000258</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000258</idno>
<idno type="wicri:Area/Ncbi/Merge">000228</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Increased Survival after Gemfibrozil Treatment of Severe Mouse Influenza<xref ref-type="fn" rid="fn2">▿</xref>
 </title>
<author><name sortKey="Budd, Alison" sort="Budd, Alison" uniqKey="Budd A" first="Alison" last="Budd">Alison Budd</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Alleva, Lisa" sort="Alleva, Lisa" uniqKey="Alleva L" first="Lisa" last="Alleva">Lisa Alleva</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Alsharifi, Mohammed" sort="Alsharifi, Mohammed" uniqKey="Alsharifi M" first="Mohammed" last="Alsharifi">Mohammed Alsharifi</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Koskinen, Aulikki" sort="Koskinen, Aulikki" uniqKey="Koskinen A" first="Aulikki" last="Koskinen">Aulikki Koskinen</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Smythe, Victoria" sort="Smythe, Victoria" uniqKey="Smythe V" first="Victoria" last="Smythe">Victoria Smythe</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mullbacher, Arno" sort="Mullbacher, Arno" uniqKey="Mullbacher A" first="Arno" last="Müllbacher">Arno Müllbacher</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wood, Jeff" sort="Wood, Jeff" uniqKey="Wood J" first="Jeff" last="Wood">Jeff Wood</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Clark, Ian" sort="Clark, Ian" uniqKey="Clark I" first="Ian" last="Clark">Ian Clark</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Antimicrobial Agents and Chemotherapy</title>
<idno type="ISSN">0066-4804</idno>
<idno type="eISSN">1098-6596</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Anti-Inflammatory Agents (administration & dosage)</term>
<term>Anti-Inflammatory Agents (therapeutic use)</term>
<term>Gemfibrozil (administration & dosage)</term>
<term>Gemfibrozil (therapeutic use)</term>
<term>Hypolipidemic Agents (administration & dosage)</term>
<term>Hypolipidemic Agents (therapeutic use)</term>
<term>Inflammation (drug therapy)</term>
<term>Inflammation (mortality)</term>
<term>Inflammation (virology)</term>
<term>Influenza A Virus, H2N2 Subtype (drug effects)</term>
<term>Influenza A Virus, H2N2 Subtype (pathogenicity)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Orthomyxoviridae Infections (drug therapy)</term>
<term>Orthomyxoviridae Infections (immunology)</term>
<term>Orthomyxoviridae Infections (mortality)</term>
<term>Orthomyxoviridae Infections (virology)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anti-inflammatoires (administration et posologie)</term>
<term>Anti-inflammatoires (usage thérapeutique)</term>
<term>Gemfibrozil (administration et posologie)</term>
<term>Gemfibrozil (usage thérapeutique)</term>
<term>Hypolipémiants (administration et posologie)</term>
<term>Hypolipémiants (usage thérapeutique)</term>
<term>Infections à Orthomyxoviridae (immunologie)</term>
<term>Infections à Orthomyxoviridae (mortalité)</term>
<term>Infections à Orthomyxoviridae (traitement médicamenteux)</term>
<term>Infections à Orthomyxoviridae (virologie)</term>
<term>Inflammation (mortalité)</term>
<term>Inflammation (traitement médicamenteux)</term>
<term>Inflammation (virologie)</term>
<term>Résultat thérapeutique</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Sous-type H2N2 du virus de la grippe A ()</term>
<term>Sous-type H2N2 du virus de la grippe A (pathogénicité)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Inflammatory Agents</term>
<term>Gemfibrozil</term>
<term>Hypolipidemic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term>
<term>Gemfibrozil</term>
<term>Hypolipidemic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anti-inflammatoires</term>
<term>Gemfibrozil</term>
<term>Hypolipémiants</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Inflammation</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à Orthomyxoviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Inflammation</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à Orthomyxoviridae</term>
<term>Inflammation</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Sous-type H2N2 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à Orthomyxoviridae</term>
<term>Inflammation</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-inflammatoires</term>
<term>Gemfibrozil</term>
<term>Hypolipémiants</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à Orthomyxoviridae</term>
<term>Inflammation</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Inflammation</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Résultat thérapeutique</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Sous-type H2N2 du virus de la grippe A</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Gemfibrozil, an agent that inhibits production of proinflammatory cytokines in addition to its clinically useful lipid-lowering activity, increased survival in BALB/c mice that were already ill from infection by influenza virus A/Japan/305/57 (H2N2). Gemfibrozil was administered intraperitoneally once daily from days 4 to 10 after intranasal exposure to the virus. Survival increased from 26% in vehicle-treated mice (<italic>n</italic>
 = 50) to 52% in mice given gemfibrozil at 60 mg/kg/day (<italic>n</italic>
 = 46) (<italic>P</italic>
 = 0.0026). If this principle translates to patients, a drug already approved for human use, albeit by a different route for another purpose, might be adapted relatively fast for use against influenza, conceivably including human infection with a derivative of the avian H5N1 strain.</p>
</div>
</front>
</TEI>
<double pmid="17562808"><pmc><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Increased Survival after Gemfibrozil Treatment of Severe Mouse Influenza<xref ref-type="fn" rid="fn2">▿</xref>
 </title>
<author><name sortKey="Budd, Alison" sort="Budd, Alison" uniqKey="Budd A" first="Alison" last="Budd">Alison Budd</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Alleva, Lisa" sort="Alleva, Lisa" uniqKey="Alleva L" first="Lisa" last="Alleva">Lisa Alleva</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Alsharifi, Mohammed" sort="Alsharifi, Mohammed" uniqKey="Alsharifi M" first="Mohammed" last="Alsharifi">Mohammed Alsharifi</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Koskinen, Aulikki" sort="Koskinen, Aulikki" uniqKey="Koskinen A" first="Aulikki" last="Koskinen">Aulikki Koskinen</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Smythe, Victoria" sort="Smythe, Victoria" uniqKey="Smythe V" first="Victoria" last="Smythe">Victoria Smythe</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mullbacher, Arno" sort="Mullbacher, Arno" uniqKey="Mullbacher A" first="Arno" last="Müllbacher">Arno Müllbacher</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wood, Jeff" sort="Wood, Jeff" uniqKey="Wood J" first="Jeff" last="Wood">Jeff Wood</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Clark, Ian" sort="Clark, Ian" uniqKey="Clark I" first="Ian" last="Clark">Ian Clark</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">17562808</idno>
<idno type="pmc">1932503</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1932503</idno>
<idno type="RBID">PMC:1932503</idno>
<idno type="doi">10.1128/AAC.00219-07</idno>
<date when="2007">2007</date>
<idno type="wicri:Area/Pmc/Corpus">000263</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000263</idno>
<idno type="wicri:Area/Pmc/Curation">000263</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000263</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000B61</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000B61</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Increased Survival after Gemfibrozil Treatment of Severe Mouse Influenza<xref ref-type="fn" rid="fn2">▿</xref>
 </title>
<author><name sortKey="Budd, Alison" sort="Budd, Alison" uniqKey="Budd A" first="Alison" last="Budd">Alison Budd</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Alleva, Lisa" sort="Alleva, Lisa" uniqKey="Alleva L" first="Lisa" last="Alleva">Lisa Alleva</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Alsharifi, Mohammed" sort="Alsharifi, Mohammed" uniqKey="Alsharifi M" first="Mohammed" last="Alsharifi">Mohammed Alsharifi</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Koskinen, Aulikki" sort="Koskinen, Aulikki" uniqKey="Koskinen A" first="Aulikki" last="Koskinen">Aulikki Koskinen</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Smythe, Victoria" sort="Smythe, Victoria" uniqKey="Smythe V" first="Victoria" last="Smythe">Victoria Smythe</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mullbacher, Arno" sort="Mullbacher, Arno" uniqKey="Mullbacher A" first="Arno" last="Müllbacher">Arno Müllbacher</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wood, Jeff" sort="Wood, Jeff" uniqKey="Wood J" first="Jeff" last="Wood">Jeff Wood</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Clark, Ian" sort="Clark, Ian" uniqKey="Clark I" first="Ian" last="Clark">Ian Clark</name>
<affiliation><nlm:aff id="aff1"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Antimicrobial Agents and Chemotherapy</title>
<idno type="ISSN">0066-4804</idno>
<idno type="eISSN">1098-6596</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Gemfibrozil, an agent that inhibits production of proinflammatory cytokines in addition to its clinically useful lipid-lowering activity, increased survival in BALB/c mice that were already ill from infection by influenza virus A/Japan/305/57 (H2N2). Gemfibrozil was administered intraperitoneally once daily from days 4 to 10 after intranasal exposure to the virus. Survival increased from 26% in vehicle-treated mice (<italic>n</italic>
 = 50) to 52% in mice given gemfibrozil at 60 mg/kg/day (<italic>n</italic>
 = 46) (<italic>P</italic>
 = 0.0026). If this principle translates to patients, a drug already approved for human use, albeit by a different route for another purpose, might be adapted relatively fast for use against influenza, conceivably including human infection with a derivative of the avian H5N1 strain.</p>
</div>
</front>
</TEI>
</pmc>
<pubmed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Increased survival after gemfibrozil treatment of severe mouse influenza.</title>
<author><name sortKey="Budd, Alison" sort="Budd, Alison" uniqKey="Budd A" first="Alison" last="Budd">Alison Budd</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Biochemistry and Molecular Biology, Australian National University, Canberra, ACT, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>School of Biochemistry and Molecular Biology, Australian National University, Canberra, ACT</wicri:regionArea>
<wicri:noRegion>ACT</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Alleva, Lisa" sort="Alleva, Lisa" uniqKey="Alleva L" first="Lisa" last="Alleva">Lisa Alleva</name>
</author>
<author><name sortKey="Alsharifi, Mohammed" sort="Alsharifi, Mohammed" uniqKey="Alsharifi M" first="Mohammed" last="Alsharifi">Mohammed Alsharifi</name>
</author>
<author><name sortKey="Koskinen, Aulikki" sort="Koskinen, Aulikki" uniqKey="Koskinen A" first="Aulikki" last="Koskinen">Aulikki Koskinen</name>
</author>
<author><name sortKey="Smythe, Victoria" sort="Smythe, Victoria" uniqKey="Smythe V" first="Victoria" last="Smythe">Victoria Smythe</name>
</author>
<author><name sortKey="Mullbacher, Arno" sort="Mullbacher, Arno" uniqKey="Mullbacher A" first="Arno" last="Müllbacher">Arno Müllbacher</name>
</author>
<author><name sortKey="Wood, Jeff" sort="Wood, Jeff" uniqKey="Wood J" first="Jeff" last="Wood">Jeff Wood</name>
</author>
<author><name sortKey="Clark, Ian" sort="Clark, Ian" uniqKey="Clark I" first="Ian" last="Clark">Ian Clark</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17562808</idno>
<idno type="pmid">17562808</idno>
<idno type="doi">10.1128/AAC.00219-07</idno>
<idno type="wicri:Area/PubMed/Corpus">000281</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000281</idno>
<idno type="wicri:Area/PubMed/Curation">000281</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000281</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000258</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000258</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Increased survival after gemfibrozil treatment of severe mouse influenza.</title>
<author><name sortKey="Budd, Alison" sort="Budd, Alison" uniqKey="Budd A" first="Alison" last="Budd">Alison Budd</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Biochemistry and Molecular Biology, Australian National University, Canberra, ACT, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>School of Biochemistry and Molecular Biology, Australian National University, Canberra, ACT</wicri:regionArea>
<wicri:noRegion>ACT</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Alleva, Lisa" sort="Alleva, Lisa" uniqKey="Alleva L" first="Lisa" last="Alleva">Lisa Alleva</name>
</author>
<author><name sortKey="Alsharifi, Mohammed" sort="Alsharifi, Mohammed" uniqKey="Alsharifi M" first="Mohammed" last="Alsharifi">Mohammed Alsharifi</name>
</author>
<author><name sortKey="Koskinen, Aulikki" sort="Koskinen, Aulikki" uniqKey="Koskinen A" first="Aulikki" last="Koskinen">Aulikki Koskinen</name>
</author>
<author><name sortKey="Smythe, Victoria" sort="Smythe, Victoria" uniqKey="Smythe V" first="Victoria" last="Smythe">Victoria Smythe</name>
</author>
<author><name sortKey="Mullbacher, Arno" sort="Mullbacher, Arno" uniqKey="Mullbacher A" first="Arno" last="Müllbacher">Arno Müllbacher</name>
</author>
<author><name sortKey="Wood, Jeff" sort="Wood, Jeff" uniqKey="Wood J" first="Jeff" last="Wood">Jeff Wood</name>
</author>
<author><name sortKey="Clark, Ian" sort="Clark, Ian" uniqKey="Clark I" first="Ian" last="Clark">Ian Clark</name>
</author>
</analytic>
<series><title level="j">Antimicrobial agents and chemotherapy</title>
<idno type="ISSN">0066-4804</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Anti-Inflammatory Agents (administration & dosage)</term>
<term>Anti-Inflammatory Agents (therapeutic use)</term>
<term>Gemfibrozil (administration & dosage)</term>
<term>Gemfibrozil (therapeutic use)</term>
<term>Hypolipidemic Agents (administration & dosage)</term>
<term>Hypolipidemic Agents (therapeutic use)</term>
<term>Inflammation (drug therapy)</term>
<term>Inflammation (mortality)</term>
<term>Inflammation (virology)</term>
<term>Influenza A Virus, H2N2 Subtype (drug effects)</term>
<term>Influenza A Virus, H2N2 Subtype (pathogenicity)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Orthomyxoviridae Infections (drug therapy)</term>
<term>Orthomyxoviridae Infections (immunology)</term>
<term>Orthomyxoviridae Infections (mortality)</term>
<term>Orthomyxoviridae Infections (virology)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anti-inflammatoires (administration et posologie)</term>
<term>Anti-inflammatoires (usage thérapeutique)</term>
<term>Gemfibrozil (administration et posologie)</term>
<term>Gemfibrozil (usage thérapeutique)</term>
<term>Hypolipémiants (administration et posologie)</term>
<term>Hypolipémiants (usage thérapeutique)</term>
<term>Infections à Orthomyxoviridae (immunologie)</term>
<term>Infections à Orthomyxoviridae (mortalité)</term>
<term>Infections à Orthomyxoviridae (traitement médicamenteux)</term>
<term>Infections à Orthomyxoviridae (virologie)</term>
<term>Inflammation (mortalité)</term>
<term>Inflammation (traitement médicamenteux)</term>
<term>Inflammation (virologie)</term>
<term>Résultat thérapeutique</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Sous-type H2N2 du virus de la grippe A ()</term>
<term>Sous-type H2N2 du virus de la grippe A (pathogénicité)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Inflammatory Agents</term>
<term>Gemfibrozil</term>
<term>Hypolipidemic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term>
<term>Gemfibrozil</term>
<term>Hypolipidemic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anti-inflammatoires</term>
<term>Gemfibrozil</term>
<term>Hypolipémiants</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Inflammation</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à Orthomyxoviridae</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Inflammation</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à Orthomyxoviridae</term>
<term>Inflammation</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Sous-type H2N2 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à Orthomyxoviridae</term>
<term>Inflammation</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anti-inflammatoires</term>
<term>Gemfibrozil</term>
<term>Hypolipémiants</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à Orthomyxoviridae</term>
<term>Inflammation</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Inflammation</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Résultat thérapeutique</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Sous-type H2N2 du virus de la grippe A</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Gemfibrozil, an agent that inhibits production of proinflammatory cytokines in addition to its clinically useful lipid-lowering activity, increased survival in BALB/c mice that were already ill from infection by influenza virus A/Japan/305/57 (H2N2). Gemfibrozil was administered intraperitoneally once daily from days 4 to 10 after intranasal exposure to the virus. Survival increased from 26% in vehicle-treated mice (n = 50) to 52% in mice given gemfibrozil at 60 mg/kg/day (n = 46) (P = 0.0026). If this principle translates to patients, a drug already approved for human use, albeit by a different route for another purpose, might be adapted relatively fast for use against influenza, conceivably including human infection with a derivative of the avian H5N1 strain.</div>
</front>
</TEI>
</pubmed>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Ncbi/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000228 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000228 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Ncbi
   |étape=   Merge
   |type=    RBID
   |clé=     PMC:1932503
   |texte=   Increased Survival after Gemfibrozil Treatment of Severe Mouse Influenza▿ 
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i   -Sk "pubmed:17562808" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a H2N2V1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration H2N2

Increased Survival after Gemfibrozil Treatment of Severe Mouse Influenza▿

Increased Survival after Gemfibrozil Treatment of Severe Mouse Influenza▿

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki